[2]Pillarisetti K, Powers G, Luistro L, et al.Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549. doi: 10.1182/bloodadvances.2020002393. [3]Smith, E., Olson, K., Haber, L. e...
Patty A.Culp,Jeremiah D.Degenhardt,Danielle E.Dettling,ChadMay Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy Chapter Nine - T-cell engaging bispecific antibody therapy网页链接 Ganesan, R., Chennupati, V., Ramachandran, B. et al. Selective recruitment of γδ...
1.Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 ...
关键词: cancer immunotherapy, bispecific antibodies, T cell engaging bispecific antibodies, potency of bispecific antibodies, TDCC, bivalent CD3 binding DOI: 10.1016/j.pharmthera.2017.08.005 被引量: 10 年份: 2017 收藏 引用 批量引用 报错 分享 全部来源 求助全文 全文购买 Elsevier 国家科技图书文...
The approval of epcoritamab was supported by findings from the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which 148 patients with CD20+ DLBCL demonstrated an overall response rate of 61% with the T cell engaging bispecific antibody. This included a complete response rate of 38% and ...
T 细胞接合双特异性抗体(T cell engaging bispecific antibody)机制与 CAR-T 疗法相似,都基于 T 细胞重定向而实现对 B 细胞淋巴瘤的杀伤。两者各有利弊,CAR-T 疗法在现有临床数据中表现出更高的响应率和缓解持续时间,不过双特异性抗体作为「现货型」疗法,能够克服 CAR-T 疗法生产周期长的短板。
A bi-specific antibody that binds both T cells and a tumor-specific intracellular antigen shows therapeutic promise in mouse models of cancer. Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) mole
[2]. Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. ...
[1]. Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. ...
cell-engaging bispecific antibodies (TCBs), and to capture clinical toxicities not predicted by conventional tissue-based models as well as inter-patient variabilities in TCB responses. We analysed the mechanisms of T-cell-mediated damage of neoplastic and donor-matched healthy epithelia at a single-...